Jennison Associates’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-897,775
| Closed | -$56.3M | – | 572 |
|
|
2026
Q1 | $56.3M | Sell |
897,775
-4,570,520
| -84% | -$366M | 0.04% | 205 |
|
|
2025
Q4 | $521M | Buy |
5,468,295
+529,549
| +11% | +$51.9M | 0.31% | 43 |
|
|
2025
Q3 | $482M | Buy |
4,938,746
+2,823,744
| +134% | +$292M | 0.28% | 44 |
|
|
2025
Q2 | $227M | Buy |
2,115,002
+1,186,949
| +128% | +$120M | 0.13% | 75 |
|
|
2025
Q1 | $93.6M | Sell |
928,053
-1,014,902
| -52% | -$102M | 0.07% | 136 |
|
|
2024
Q4 | $174M | Buy |
1,942,955
+414,774
| +27% | +$36.5M | 0.11% | 91 |
|
|
2024
Q3 | $128M | Sell |
1,528,181
-511,463
| -25% | -$40.3M | 0.08% | 110 |
|
|
2024
Q2 | $157M | Buy |
2,039,644
+820,324
| +67% | +$60M | 0.1% | 84 |
|
|
2024
Q1 | $83.5M | Sell |
1,219,320
-8,513
| -0.7% | -$547K | 0.06% | 141 |
|
|
2023
Q4 | $71M | Buy |
1,227,833
+15,596
| +1% | +$832K | 0.05% | 147 |
|
|
2023
Q3 | $64M | Buy |
1,212,237
+107,093
| +10% | +$5.62M | 0.05% | 151 |
|
|
2023
Q2 | $59.8M | Buy |
1,105,144
+23,098
| +2% | +$1.21M | 0.05% | 166 |
|
|
2023
Q1 | $54.1M | Buy |
+1,082,046
| New | +$51M | 0.05% | 174 |
|
|
2021
Q2 | – | Sell |
-801,037
| Closed | -$31M | – | 679 |
|
|
2021
Q1 | $31M | Sell |
801,037
-1,047,114
| -57% | -$39.6M | 0.02% | 295 |
|
|
2020
Q4 | $66.4M | Sell |
1,848,151
-5,483,346
| -75% | -$198M | 0.05% | 164 |
|
|
2020
Q3 | $280M | Sell |
7,331,497
-1,650,753
| -18% | -$63.6M | 0.23% | 56 |
|
|
2020
Q2 | $315M | Sell |
8,982,250
-8,085,569
| -47% | -$291M | 0.29% | 51 |
|
|
2020
Q1 | $557M | Buy |
17,067,819
+5,709,360
| +50% | +$223M | 0.68% | 36 |
|
|
2019
Q4 | $514M | Buy |
11,358,459
+9,545,336
| +526% | +$399M | 0.52% | 46 |
|
|
2019
Q3 | $73.8M | Sell |
1,813,123
-177,487
| -9% | -$7.52M | 0.08% | 147 |
|
|
2019
Q2 | $85.6M | Sell |
1,990,610
-11,204
| -0.6% | -$431K | 0.08% | 134 |
|
|
2019
Q1 | $76.8M | Buy |
2,001,814
+376
| +0% | +$14.4K | 0.08% | 151 |
|
|
2018
Q4 | $70.7M | Buy |
2,001,438
+1,934
| +0.1% | +$70.1K | 0.08% | 154 |
|
|
2018
Q3 | $77M | Buy |
1,999,504
+16,121
| +0.8% | +$563K | 0.07% | 186 |
|
|
2018
Q2 | $64.9M | Buy |
1,983,383
+35,833
| +2% | +$1.08M | 0.06% | 224 |
|
|
2018
Q1 | $53.2M | Buy |
1,947,550
+210,832
| +12% | +$5.73M | 0.05% | 248 |
|
|
2017
Q4 | $43.1M | Sell |
1,736,718
-6,443,302
| -79% | -$178M | 0.04% | 281 |
|
|
2017
Q3 | $239M | Sell |
8,180,020
-2,459,270
| -23% | -$67.9M | 0.24% | 61 |
|
|
2017
Q2 | $295M | Buy |
10,639,290
+8,533,655
| +405% | +$226M | 0.31% | 53 |
|
|
2017
Q1 | $52.4M | Buy |
2,105,635
+317,319
| +18% | +$7.72M | 0.06% | 255 |
|
|
2016
Q4 | $38.7M | Buy |
+1,788,316
| New | +$39M | 0.04% | 308 |
|
Other funds holding BSX
Jennison Associates's BSX Position: Q2 2026 in Review
Jennison Associates sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 897,775 shares — an estimated $56.3M sold.
Jennison Associates first reported a position in BSX in Q4 2016 and held it in 31 quarters. The position peaked at $557M in Q1 2020. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Jennison Associates reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
- Jennison Associates sold 897,775 Boston Scientific shares in Q2 2026, an estimated $56.3M.
- Jennison Associates first reported a position in Boston Scientific in Q4 2016 and held it in 31 quarters.
- Jennison Associates's Boston Scientific position peaked at $557M in Q1 2020.
- 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.